Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Lymphoid 2Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1Classical hematology 1CNS 1

Conditions

Leukemia, Myeloid, Acute 76Anemia, Refractory, with Excess of Blasts 72Myelodysplastic Syndromes 69Leukemia 54Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Anemia 50Leukemia, Lymphocytic, Chronic, B-Cell 44Leukemia, Myelomonocytic, Chronic 42Lymphoma, Non-Hodgkin 41Multiple Myeloma 38Hodgkin Disease 36Myeloproliferative Disorders 34Primary Myelofibrosis 33Thrombocytopenia 32Leukemia, Myelogenous, Chronic, BCR-ABL Positive 32Lymphoma 31Neoplasms 29Anemia, Aplastic 29Congenital Abnormalities 27Anemia, Refractory 25Lymphoma, Follicular 23Lymphoma, Mantle-Cell 21Lymphoma, B-Cell, Marginal Zone 18Burkitt Lymphoma 18Lymphoma, Large B-Cell, Diffuse 17Leukemia, Myeloid, Chronic-Phase 17Venous Thromboembolism 16Lymphoma, Large-Cell, Immunoblastic 16Leukemia, Myeloid, Accelerated Phase 16Waldenstrom Macroglobulinemia 14

Interventions

sodium thiosulfate 1pegfilgrastim 1etoposide phosphate 1Rituximab 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Cytarabine 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Drug-Related Side Effects and Adverse Reactions × Classical hematology × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡